差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。
The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.
值得注意的是ATLAS试验纳入的绝大多数病人为非鳞状细胞癌，不同于培美曲赛的JMEN试验和厄洛替尼的SATURN试验。
It should be noted that the ATLAS patient population had almost no squamous cell carcinoma, in contrast to the populations of the JMEN pemetrexed trial and the SATURN erlotinib trial.
应用推荐